Veraxa Biotech Holding AG (VRXAW) Common Equity (2024 - 2025)
Veraxa Biotech Holding AG (VRXAW) posted quarterly Common Equity of -$364747.3 for Q4 2025, down 101.03% year-over-year from $35.4 million in Q4 2024, and down 101.03% quarter-over-quarter from $35.4 million in Q4 2024.
Veraxa Biotech Holding AG (VRXAW) Common Equity (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXAW) has reported Common Equity for 2 consecutive years, with -$364747.3 the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 101.03% year-over-year to -$364747.3; the TTM figure through Dec 2025 stood at -$364747.3 (down 101.03% YoY), while the FY2025 annual figure was -$364747.3, down 101.03% from the prior year.
- Common Equity eased to -$364747.3 in Q4 2025 per VRXAW's latest filing, from $35.4 million in the prior quarter.
- Across five years, Common Equity topped out at $35.4 million in Q4 2024 and bottomed at -$364747.3 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -364,747.27 |
| Dec 31, 2024 | 35.45 Mn |